Security Snapshot

Lexaria Bioscience Corp. - *W EXP 01/14/202 (LEXXW) Institutional Ownership

CUSIP: 52886N117

13F Institutional Holders and Ownership History from Q1 2021 to Q1 2026

13F reference period

n/a

Institutions Reporting

Shares (Excl. Options)

n/a

Price

$0.04

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

SEC-reported price per share
$0.04
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • LEXXW - Lexaria Bioscience Corp. - *W EXP 01/14/202 is tracked under CUSIP 52886N117.
  • 13F reference-period holder data is not available.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder data for the Q2 2026 reference period is not available.
  • Available periods remain in the history table; they do not substitute for the headline period.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC evidence

Security key

52886N117

13F reference period

n/a

13F holders

13D/G owners

0

CIK / CUSIP context first

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
21
Headline period
n/a
Rows shown
1-21 of 21
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 0 $0 -$97 $0.04 0
2025 Q4 23,119 $97 -$3,397 $0.00 2
2025 Q3 85,026 $6,802 -$142 $0.08 4
2025 Q2 45,446 $4,545 $0.10 2
2025 Q1 45,446 $14,989 -$447 $0.35 2
2024 Q4 46,530 $39,334 -$18,614 $0.81 3
2024 Q3 69,516 $63,886 -$60,247 $0.92 3
2024 Q2 135,473 $109,204 +$75,460 $0.81 3
2024 Q1 41,850 $62,776 -$104,347 $1.50 3
2023 Q4 133,842 $123,389 -$45,142 $0.45 3
2023 Q3 350,928 $133,935 -$7,203 $0.21 5
2023 Q2 386,700 $125,362 +$562 $0.22 5
2023 Q1 384,148 $389,197 +$20,576 $0.58 3
2022 Q4 351,259 $303,113 -$22,015 $0.40 4
2022 Q3 532,525 $991,000 -$143,499 $1.52 4
2022 Q2 591,760 $593,000 -$61,717 $0.70 5
2022 Q1 680,515 $802,000 +$11,956 $0.90 4
2021 Q4 666,881 $1,204,000 +$114,724 $1.51 5
2021 Q3 456,921 $1,288,000 -$1,051,328 $2.11 3
2021 Q2 887,101 $2,581,000 +$276,682 $2.51 4
2021 Q1 776,855 $2,111,000 +$2,111,000 $2.40 4
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .